Efficacy and safety of esketamine hydrochloride adjunct to sufentanil in non-surgical patients under mechanical ventilation in the ICU (SENSATION trial): protocol for a multicentre, single-blind, randomised controlled trial.
Yi Long, Donghuang Hong, Haibin Ni, Dandan Zhou, Tingfa Zhou, Songwu Liu, Xiang Luo, Qian Liu, Rui Li, Zhengying Jiang, Lu Ke
BMJ Open September 25, 2024 DOI: 10.1136/bmjopen-2024-084469 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 132 |
| Population | Non-surgical patients under mechanical ventilation in the ICU |
| Interventions | Sufentanil Esketamine |
| Dose | 0.2 mg/kg/hour |
| Topics | Esketamine Ketamine |
| Keywords | Pain management Randomized controlled trial Critical care medicine Esketamine therapy Clinical trials Anesthesiology |
| Citations | 1 |
| Key findings | The trial is ongoing; no results are reported. |
Abstract
Pain is common in patients receiving mechanical ventilation in the intensive care unit (ICU). Intravenous opioids are recommended as first-line therapy for pain management; however, opioids have adverse side effects. Based on low-quality evidence, low-dose ketamine is therefore recommended as an opioid adjunct to reduce opioid consumption. Esketamine is an alternative to ketamine with greater efficacy and fewer side effects. However, evidence on the use of esketamine in patients receiving mechanical ventilation is lacking. This study investigates the efficacy and safety of esketamine as an adjunct to sufentanil for analgesic therapy in non-surgical ICU patients under mechanical ventilation. This ongoing multicentre, single-blind, randomised controlled trial is being conducted at six ICUs in China. 132 non-surgical patients under mechanical ventilation will be randomly assigned to the standard care and S-ketamine groups at a 1:1 ratio. Patients in the standard care group received a minimal dose of sufentanil as the sole analgesic agent. Patients in the S-ketamine group received a minimal dose of sufentanil in addition to an esketamine infusion at a fixed rate of 0.2 mg/kg/hour for analgesia. The primary outcome is mean hourly sufentanil consumption during the treatment period. This study was approved by the Ethics Committee of Chongqing University Cancer Hospital (CZLS2022067-A). Participants are required to provide informed consent. The results of this trial will be reported in peer-reviewed journals and presented at conferences. ChiCTR2200058933.
Comparable studies
Other randomized controlled trials on esketamine, most cited first.
Citations in the library
Cites 2
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study Drug Design, Development and Therapy December 1, 2019